BioCentury | Feb 10, 2017
Emerging Company Profile

Improving the original immunotherapy

...compounds would avoid the manufacturing and scalability challenges of CAR Ts. Lead compounds CUE-101 and CUE-102...
...evaluate CUE-101 as monotherapy, but the company also plans to test combinations with checkpoint inhibitors. CUE-102...
...M. “Cancer’s phoenix.” BioCentury Innovations (2016) Li, V. “Activation on cue.” BioCentury (2017) Virginia Li, Staff Writer CUE-101 CUE-102 Cue...
Items per page:
1 - 1 of 1